New Clinical Studies Reinforce Trinity Elite’s Efficacy in Bone Fusion Procedures 

 Five recent clinical publications have reinforced the efficacy and safety of Trinity Elite™, an allograft with viable cells, further establishing its position as a leading autograft alternative for bone fusion procedures. These studies demonstrate the product’s versatility and effectiveness across various surgical applications and patient populations. 

Key Findings: 

Multi-Level ACDF Fusion Success 

Goldman et al. (2024) in the Journal of Spine Surgery found that Trinity Elite resulted in high fusion rates, comparable to those reported for autograft, in a real-world population of up to 4 ACDF levels, with no graft-related complications or cage migration/subsidence. 

*Study not company sponsored. 

Lumbar Spinal Fusion Success A study by Lansford et al. (2024) published in the International Journal of Spine Surgery revealed that Trinity Elite achieved high rates of bone fusion in spinal procedures, regardless of the surgical approach employed. 

Patients experienced improved clinical outcomes and the product demonstrated a favorable safety profile. 

Foot and Ankle Arthrodesis in High-Risk Patients Donaghue et al. (2024) reported in Orthopedic Reviews that Trinity Elite showed fusion rates that were higher than or comparable to those typically seen with autografts in foot and ankle arthrodesis procedures. 

This finding is significant for high-risk patients, as it supports Trinity Elite as a safe and effective autograft substitute in this challenging population. 

Comparable Results to Local Bone in Lumbar Fusion Research by Sayeed et al. (2024) in JAAOS Global Research & Reviews found that Trinity Elite resulted in similar radiographic fusion rates when compared to treatments using local bone in posterolateral lumbar fusion procedures. 

This equivalence further solidifies Trinity Elite’s position as a viable alternative to traditional autograft techniques. 

Consistent Performance Across Patient Risk Factors Russo et al. (2024) published findings in BMC Musculoskeletal Disorders demonstrating that surgical interventions using Trinity Elite resulted in high fusion rates, positive patient-reported outcomes, and strong safety measures, regardless of individual patient risk factors. 

Proven Track Record 

These new studies provide compelling evidence for the efficacy and safety of Trinity Elite across a range of orthopedic applications. From spinal fusions to foot and ankle procedures, and even in high-risk patient populations, Trinity Elite continues to demonstrate its value as an autograft alternative. These findings offer reassurance and support for surgeons and patients using Trinity Elite in bone fusion procedures. 

With over 15 years of clinical use and over 350,000 procedures performed, Trinity allografts have consistently proven safe and effective for bone repair, including in patients with co-morbidities. 

About MTF Biologics 

Trinity Elite is exclusively processed by MTF Biologics, a global non-profit organization with 35 years of experience in allograft technologies. 

MTF Biologics is known for setting industry standards through rigorous donor screening processes. Their commitment to quality is evident in their acceptance rate of less than 2% of donated tissue while maintaining a broad recovery network. 

To learn more about Trinity Elite and how it can benefit your patients, visit the official product page or consult the full text of these recent publications for in-depth insights into its clinical performance.